Carpenter Technology(CRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRS Carpenter Technology

Trading 01-21 13:36:15 EST

332.26

-0.09

-0.03%

High336.64	Low329.06	Vol181.58K
Open333.14	D1 Closing332.35	Amplitude2.28%
Mkt Cap16.55B	Tradable Cap16.11B	Total Shares49.82M
T/O60.44M	T/O Rate0.37%	Tradable Shares48.50M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRS","market":"US","secType":"STK","nameCN":"Carpenter Technology","latestPrice":332.255,"timestamp":1769020568881,"preClose":332.35,"halted":0,"volume":181584,"delay":0,"changeRate":-0.00028584323755085684,"floatShares":48497746,"shares":49818822,"eps":8.177718,"marketStatus":"Trading","change":-0.095,"latestTime":"01-21 13:36:15 EST","open":333.136,"high":336.635,"low":329.06,"amount":60435640.3248,"amplitude":0.022792,"askPrice":332.63,"askSize":77,"bidPrice":332,"bidSize":9,"shortable":3,"etf":0,"ttmEps":8.177718,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1769029200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":332.35,"dividendRate":0.002408,"preHourTrading":{"tag":"盘前","latestPrice":334,"preClose":332.35,"latestTime":"09:20 EST","volume":83,"amount":27653.7408,"timestamp":1769005213223,"change":1.65,"changeRate":0.004965,"amplitude":0.011584},"postHourTrading":{"tag":"盘后","latestPrice":332.35,"preClose":332.35,"latestTime":"19:41 EST","volume":55759,"amount":18530734.7654,"timestamp":1768956074426,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.385796,"impliedVol":0.558,"impliedVolPercentile":0.8486},"requestUrl":"/m/hq/s/CRS/tweets","defaultTab":"tweets","newsList":[{"id":"2604854551","title":"Is Dividend Hike, Investment-Grade Rating and New Debt Deal Altering The Investment Case For Carpenter Technology (CRS)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2604854551","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604854551?lang=en_us&edition=fundamental","pubTime":"2026-01-19 12:34","pubTimestamp":1768797250,"startTime":"0","endTime":"0","summary":"Carpenter Technology Corporation recently declared a past quarterly cash dividend of US$0.20 per share, payable on March 5, 2026, to shareholders of record as of January 27, 2026, while also closing a US$700 million senior notes offering at 5.625% interest maturing in 2034 and receiving a Fitch credit rating upgrade to BBB-.\nThis combination of an ongoing dividend, long-term financing, and an investment-grade credit rating signals stronger balance sheet flexibility and an emphasis on...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2055000-choice1-main-header/1585186785008","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2055000-choice1-main-header/1585186785008"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-crs/carpenter-technology/news/is-dividend-hike-investment-grade-rating-and-new-debt-deal-a","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-crs/carpenter-technology/news/is-dividend-hike-investment-grade-rating-and-new-debt-deal-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CRS.AU","CRS"],"gpt_icon":0},{"id":"2604911862","title":"Carpenter Technology Partners Keeps Quarterly Dividend at $0.20 a Share, Payable Mar. 5 to Holders of Record Jan. 27","url":"https://stock-news.laohu8.com/highlight/detail?id=2604911862","media":"MT Newswires Live","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604911862?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:35","pubTimestamp":1768599336,"startTime":"0","endTime":"0","summary":"Carpenter Technology Partners Keeps Quarterly Dividend at $0.20 a Share, Payable Mar. 5 to Holders of Record Jan. 27","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRS"],"gpt_icon":0},{"id":"2604919018","title":"Press Release: Carpenter Technology Declares Quarterly Cash Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2604919018","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604919018?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:30","pubTimestamp":1768599000,"startTime":"0","endTime":"0","summary":"PHILADELPHIA, Jan. 16, 2026  -- Carpenter Technology Corporation  announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share of common stock, payable March 5, 2026, to shareholders of record on January 27, 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B66KJ199.SGD","LU0963586101.USD","IE00B19Z4B17.USD","CRS","IE00B7SZL793.SGD","LU2065731478.USD","BK4006","IE0031619046.USD","BK4187"],"gpt_icon":0},{"id":"2604409916","title":"Analysts Offer Insights on Industrial Goods Companies: Carpenter Technology (CRS) and RELX plc (OtherRLXXF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604409916","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604409916?lang=en_us&edition=fundamental","pubTime":"2026-01-17 04:30","pubTimestamp":1768595418,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Industrial Goods sector as 2 analysts just weighed in on Carpenter Technology (CRS – Research Report) a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-industrial-goods-companies-carpenter-technology-crs-and-relx-plc-otherrlxxf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-industrial-goods-companies-carpenter-technology-crs-and-relx-plc-otherrlxxf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4563","LU2065731478.USD","BK4526","IE00B19Z4B17.USD","RLX","BK4075","BK4006","BK4187","IE00B7SZL793.SGD","IE0031619046.USD","LU0963586101.USD","IE00B66KJ199.SGD","BK4551","CRS"],"gpt_icon":0},{"id":"1176069226","title":"Think Overseas Income Escapes Tax Authorities? Time to Debunk This \"Look-Back Period\" Myth","url":"https://stock-news.laohu8.com/highlight/detail?id=1176069226","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176069226?lang=en_us&edition=fundamental","pubTime":"2026-01-16 21:12","pubTimestamp":1768569171,"startTime":"0","endTime":"0","summary":"The wave of compliance self-inspections targeting overseas income that began in early 2026, characterized by its intensity and the depth of its retrospective reach, has indeed caused significant...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065731478.USD","CRS","BK4006","BK4187","IE00B19Z4B17.USD","IE00B7SZL793.SGD","IE0031619046.USD","IE00B66KJ199.SGD","LU0963586101.USD"],"gpt_icon":0},{"id":"2603400937","title":"Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs","url":"https://stock-news.laohu8.com/highlight/detail?id=2603400937","media":"prnewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603400937?lang=en_us&edition=fundamental","pubTime":"2026-01-16 09:00","pubTimestamp":1768525200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Jan. 16, 2026 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines forautoimmune disease, solid tumors and hematological malignancies indications, announced that it recently presented at the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco. At the conference, Antengene shared the latest data and clinical development plans for its core clinical asset, ATG-022 , as well as R&D progress on ATG-125 , its steric hindrance masking AnTenGager T cell engager  platform, and other key preclinical programs.Advancing clinical development across 1L to 3L gastric cancer: Antengene is currently conducting the Phase I/II CLINCH study and","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-presents-at-jpm-strong-clinical-data-update-and-strategic-focus-on-next-generation-adcs-and-tces-302662555.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1084165304.USD","BK4581","IE00BFXG1179.USD","LU2756315664.SGD","ACR","LU0345769631.USD","LU1244550494.USD","ORR.AU","IE0034235295.USD","LU0345770993.USD","IE0034235188.USD","IE00BN8TJ469.HKD","LU0417517546.SGD","LU0787776722.HKD","LU1064131342.USD","IE00BKVL7J92.USD","LU0106831901.USD","LU0170899867.USD","LU1974910355.USD","LU0943347566.SGD","LU2746668461.USD","CRS.AU","LU0820562030.AUD","LU2264538146.SGD","LU2430703095.HKD","LU0251132253.USD","LU1629891620.HKD","IND","IND.AU","ACR.AU","IE00B3S45H60.SGD","LU0345770308.USD","CRS","LU0106261372.USD","LU0208291251.USD","LU1670627923.USD","LU0006306889.USD","LU2106854487.HKD","LU2065731478.USD","ORR","IE00BHPRN162.USD","LU0820561818.USD","LU0683600562.USD","BK4534","LU0211328371.USD","LU2023250843.SGD","BK7508","CR","LU0868494617.USD"],"gpt_icon":0},{"id":"2602376690","title":"Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2602376690","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602376690?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:04","pubTimestamp":1767963840,"startTime":"0","endTime":"0","summary":"Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential oppor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/09/3216066/0/en/Cartesian-Therapeutics-Highlights-Recent-Progress-and-Outlines-2026-Outlook.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4187","MG","LU2065732104.USD","IE0031619046.USD","BK4006","IE00B19Z4B17.USD","CAR","BK4139","BK4230","BK4097","PRGS","CRS","IE00B7SZL793.SGD","BK4077","LU2065731478.USD","IE00B66KJ199.SGD","SLE","IND","RNAC","LU0963586101.USD","BK4123"],"gpt_icon":0},{"id":"2601480647","title":"SeaStar Medical Announces 2026 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2601480647","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601480647?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:13","pubTimestamp":1767791580,"startTime":"0","endTime":"0","summary":"Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer base Advance SeaStar Medical’s first-in-class SCD therapy for the adult AKI indication – a potent","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/07/3214506/0/en/SeaStar-Medical-Announces-2026-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","LU2065731478.USD","IE00B66KJ199.SGD","BK4006","IE0031619046.USD","CRS","IE00B7SZL793.SGD","BK4187","SCD","LU0963586101.USD"],"gpt_icon":0},{"id":"2601824506","title":"We Think Caprice Resources (ASX:CRS) Can Afford To Drive Business Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2601824506","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601824506?lang=en_us&edition=fundamental","pubTime":"2026-01-07 09:11","pubTimestamp":1767748304,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Caprice Resources...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-crs/caprice-resources-shares/news/we-think-caprice-resources-asxcrs-can-afford-to-drive-busine","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-crs/caprice-resources-shares/news/we-think-caprice-resources-asxcrs-can-afford-to-drive-busine","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7095","BK4187","LU0963586101.USD","IE00B19Z4B17.USD","IE00B7SZL793.SGD","IE0031619046.USD","IE00B66KJ199.SGD","BK4006","CRS.AU","LU2065731478.USD","CRS"],"gpt_icon":0},{"id":"2601281810","title":"Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2601281810","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601281810?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:00","pubTimestamp":1767708000,"startTime":"0","endTime":"0","summary":"Autolus will evaluate Cellares’ fully automated, high-throughput manufacturing platform in preparation for expansion into new indicationsSOUTH SAN FRANCISCO, Calif. and LONDON, Jan.  06, 2026  (GLOBE ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/06/3213731/0/en/Autolus-Therapeutics-to-Evaluate-Automated-Manufacturing-of-AUCATZYL-obe-cel-on-the-Cellares-Cell-Shuttle-Platform.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","BK4006","LU0985320562.USD","BK4007","BK4084","BK4219","LU0963586101.USD","BK4533","LU1571399168.USD","BK4539","BK4581","ALL","AMT","BK4588","IE00B66KJ199.SGD","LU2065731478.USD","BK4554","LENZ","BK4139","BK4534","IDMO","BK4187","BK4585","LU1699723380.USD","IE0031619046.USD","IE00B7SZL793.SGD","CRS","BK4107","LU2355687059.USD"],"gpt_icon":0},{"id":"2601890656","title":"Carpenter Technology Corporation to Announce Second Quarter Fiscal 2026 Results in Upcoming Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2601890656","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601890656?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:31","pubTimestamp":1767706286,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carpenter Technology Corporation published the original content used to generate this news brief via GlobeNewswire  on January 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDLbNM5YM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZL793.SGD","BK4112","BK4006","IE00BGHQF748.EUR","SG9999014005.SGD","IE00B3QW5Z07.USD","CRS","LU0314104364.USD","BK4585","IE00B19Z4B17.USD","SG9999014013.SGD","SG9999014039.USD","BK4588","LU2065731478.USD","IE00B66KJ199.SGD","BK4187","LU2210150020.SGD","SG9999014021.USD","LU2095319765.USD","IE00B64PRP62.GBP","IE0031619046.USD","LU0963586101.USD","IE00BKPKM429.USD","NDAQ","LU2210149790.SGD"],"gpt_icon":0},{"id":"2595731483","title":"IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2595731483","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595731483?lang=en_us&edition=fundamental","pubTime":"2025-12-30 00:10","pubTimestamp":1767024600,"startTime":"0","endTime":"0","summary":"Enrollment in the Pivotal Phase 3 OVATION3 Study Advances Company Toward Future BLA Filing New Data from MRD Study Reinforces IMNN-001's Promise as a Potential Breakthrough Immunotherapy LAWRENCEVILLE","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/29/3211040/0/en/IMUNON-2025-A-TRANSFORMATIVE-YEAR-OF-SIGNIFICANT-CLINICAL-ADVANCES-LOOKING-AHEAD-TO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065731478.USD","IE00B19Z4B17.USD","BK4006","LU0963586101.USD","OS","PFS","BK4211","BK4097","IE00B66KJ199.SGD","BK4187","BK4195","CRS","YEAR","IE0031619046.USD","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2592951573","title":"Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2592951573","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592951573?lang=en_us&edition=fundamental","pubTime":"2025-12-17 09:00","pubTimestamp":1765933200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Dec. 17, 2025 /PRNewswire/ --Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a supplemental New Drug Application  for XPOVIO  for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma  after at least 2 lines of systemic therapy, who are ineligible for autologous stem cell transplant.Antengene has also developed AnTenGager, a proprietary T cell engager 2.0 platform featuring \"2+1\" bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-expands-xpovio-indications-in-malaysia-with-approval-in-diffuse-large-b-cell-lymphoma-302643389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK4187","IE00B7SZL793.SGD","IND.AU","LU2065731478.USD","CRS.AU","BK4006","LU0963586101.USD","IE00B66KJ199.SGD","CRS","BK7095","IE00B19Z4B17.USD","IE0031619046.USD"],"gpt_icon":0},{"id":"2591902647","title":"Kyverna Stock Rockets After Cell Therapy Helps Patients Walk Again In Rare Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2591902647","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591902647?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:48","pubTimestamp":1765810080,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics, Inc.  stock rose Monday, with a session volume of 6.80 million compared to the average volume of 696.68 thousand as per data from Benzinga Pro.The clinical-stage biopharmaceutical company shared topline data from the KYSA-8 Phase 2 trial of mivocabtagene autoleucel  in stiff person syndrome .Miv-cel is a fully human, autologous CD19-targeting CAR T-cell therapy with CD28 co-stimulation.Also Read: Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026. Stiff Person Syndrome is a rare autoimmune neurological disorder causing progressive muscle stiffness, rigidity, and painful spasms, primarily in the torso and limbs, triggered by stimuli like noise or touch, leading to falls and disability as it worsens over time.It results from the immune system mistakenly attacking nerve cells controlling muscle movement.The single-arm registrational Phase 2 trial dosed 26 patients who had an inadequate response with non-approved treatment options, and received a single d","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/15/Medical-Research.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/15/Medical-Research.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/12/49393558/kyverna-stock-rockets-after-cell-therapy-helps-patients-walk-again-in-rare-disorder","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49393558/kyverna-stock-rockets-after-cell-therapy-helps-patients-walk-again-in-rare-disorder","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4006","BK4585","BK4187","BK4588","IE00B66KJ199.SGD","KYTX","LU0963586101.USD","LU2065731478.USD","BK4139","DSI","IE0031619046.USD","CRS","IE00B7SZL793.SGD","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2591439736","title":"Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2591439736","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591439736?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:30","pubTimestamp":1765798200,"startTime":"0","endTime":"0","summary":"Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 Miv-cel ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/15/3205250/0/en/Kyverna-Therapeutics-Announces-Positive-Topline-Data-from-Registrational-KYSA-8-Trial-of-Miv-cel-KYV-101-in-Stiff-Person-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4187","CRS","CAR","DSI","LU0963586101.USD","IE00B19Z4B17.USD","BK4022","IE00B7SZL793.SGD","BK4006","IE00B66KJ199.SGD","BK4585","LU2065731478.USD","IE0031619046.USD","BK4139","BK4230","KYTX","BK4588"],"gpt_icon":0},{"id":"2590564305","title":"NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO","url":"https://stock-news.laohu8.com/highlight/detail?id=2590564305","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590564305?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:30","pubTimestamp":1765402200,"startTime":"0","endTime":"0","summary":"Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/10/3203528/0/en/NovaBridge-Presents-Positive-Ragistomig-Phase-1-Dose-Expansion-Data-at-ESMO-IO.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRS","BK4110","IE00B66KJ199.SGD","IE00B7SZL793.SGD","LFT","LU0210528500.USD","BK4187","LU2065731478.USD","BK4585","L","IE00B19Z4B17.USD","BK4588","LU0963586101.USD","LU2487616109.SGD","BK4006","IE0031619046.USD","LU0053666078.USD","BK4107"],"gpt_icon":0},{"id":"1152131178","title":"IPO Preview | Can Shima Pharma Win Market Favor in the Billion-Dollar TCE Oncology Therapy Blue Ocean?","url":"https://stock-news.laohu8.com/highlight/detail?id=1152131178","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152131178?lang=en_us&edition=fundamental","pubTime":"2025-12-09 13:18","pubTimestamp":1765257530,"startTime":"0","endTime":"0","summary":"Recently, another innovative biopharmaceutical company officially submitted its IPO application to the Hong Kong Stock Exchange. According to disclosures, Zhejiang Shima Pharmaceutical Co., Ltd.-B...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","IE00B19Z4B17.USD","LU0210528500.USD","BK4006","LU2487616109.SGD","BK4231","L","LU0963586101.USD","ORR","ADC","BK4588","LU0053666078.USD","IE00B66KJ199.SGD","LU2065731478.USD","BK4187","BK4585","IE0031619046.USD","IE00B7SZL793.SGD","CRS","BK4107"],"gpt_icon":0},{"id":"2590910366","title":"Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590910366","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590910366?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:30","pubTimestamp":1765229400,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 8, 2025 Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT),","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201984/0/en/Genmab-Announces-New-Data-from-Phase-1b-2-EPCORE-CLL-1-Highlighting-Potential-of-Epcoritamab-as-Monotherapy-and-in-Combination-for-Patients-with-Richter-Transformation-RT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","LU0963586101.USD","CR","BK4006","PFS","LU2463526074.USD","BK4097","LU2065731478.USD","BK4211","ASH","IE0031619046.USD","ORR","BK4187","BK4161","CRS","IE00B7SZL793.SGD","BK4109","OS","BK4195","IE00B66KJ199.SGD"],"gpt_icon":0},{"id":"2589355106","title":"Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2589355106","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589355106?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:35","pubTimestamp":1765200900,"startTime":"0","endTime":"0","summary":"Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune e","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201559/0/en/Autolus-Therapeutics-Presents-Initial-Clinical-Data-in-Pediatric-r-r-B-ALL-Patients-and-Other-Oncology-Data-at-the-American-Society-of-Hematology-ASH-Annual-Meeting-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0985320562.USD","IE00B66KJ199.SGD","LU1699723380.USD","FC","IE00B7SZL793.SGD","LU2355687059.USD","ORR","BK4533","OS","BK4539","BK4187","LU1571399168.USD","BK4107","ASH","LU2463526074.USD","LU2065731478.USD","BK4132","CRS","BK4022","BK4585","CR","BK4230","LU0963586101.USD","BK4007","BK4006","LENZ","BK4123","ALL","IE0031619046.USD","CAR","BK4139","BK4109","BK4161","BK4588","BK4117","IE00B19Z4B17.USD","BK4097","UCL","AFG"],"gpt_icon":0},{"id":"2589261588","title":"Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589261588","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589261588?lang=en_us&edition=fundamental","pubTime":"2025-12-06 22:30","pubTimestamp":1765031400,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in pat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201065/0/en/Genmab-Announces-Data-From-Multiple-Clinical-Trials-Showing-Treatment-with-Fixed-Duration-Epcoritamab-Led-to-Remissions-in-First-Line-Diffuse-Large-B-Cell-Lymphoma-DLBCL-and-Follic.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BR","IPI","BK4097","IE0031619046.USD","IE00B19Z4B17.USD","BK4161","OS","CR","BK4187","CRS","BK4588","IE00B66KJ199.SGD","LU1228905037.USD","LU2463526074.USD","ORR","BK4195","LU2065731478.USD","BK4093","LU0963586101.USD","BK4106","IE00B7SZL793.SGD","IE0034235188.USD","BK4548","ASH","LU0390134368.USD","LU0545562505.USD","BK4006","BK4585","BK4226","IE0009354923.USD","PFS","BK4211","BK4109","LU1228905540.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.carpentertechnology.com","stockEarnings":[{"period":"1week","weight":0.0381},{"period":"1month","weight":0.0159},{"period":"3month","weight":0.3577},{"period":"6month","weight":0.2175},{"period":"1year","weight":0.6088},{"period":"ytd","weight":0.0556}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0044},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.068},{"period":"1year","weight":0.1339},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Carpenter Technology Corporation engages in the manufacture, fabrication, and distribution of specialty metals in the United States, Europe, the Asia Pacific, Mexico, Canada, and internationally. It operates in two segments, Specialty Alloys Operations and Performance Engineered Products. The company offers specialty alloys, including titanium alloys, powder metals, stainless steels, alloy steels, and tool steels, as well as additives, and metal powders and parts. It serves aerospace, defense, medical, transportation, energy, industrial, and consumer markets. The company was founded in 1889 and is headquartered in Philadelphia, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.456522,"avgChangeRate":-0.005702},{"month":2,"riseRate":0.644444,"avgChangeRate":0.022439},{"month":3,"riseRate":0.533333,"avgChangeRate":0.000821},{"month":4,"riseRate":0.565217,"avgChangeRate":0.044931},{"month":5,"riseRate":0.543478,"avgChangeRate":0.024379},{"month":6,"riseRate":0.521739,"avgChangeRate":-0.000496},{"month":7,"riseRate":0.5,"avgChangeRate":0.022964},{"month":8,"riseRate":0.456522,"avgChangeRate":-0.007895},{"month":9,"riseRate":0.608696,"avgChangeRate":-0.003285},{"month":10,"riseRate":0.347826,"avgChangeRate":-0.015075},{"month":11,"riseRate":0.717391,"avgChangeRate":0.060126},{"month":12,"riseRate":0.608696,"avgChangeRate":0.016172}],"exchange":"NYSE","name":"Carpenter Technology","nameEN":"Carpenter Technology"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Carpenter Technology(CRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Carpenter Technology(CRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Carpenter Technology,CRS,Carpenter Technology股票,Carpenter Technology股票老虎,Carpenter Technology股票老虎国际,Carpenter Technology行情,Carpenter Technology股票行情,Carpenter Technology股价,Carpenter Technology股市,Carpenter Technology股票价格,Carpenter Technology股票交易,Carpenter Technology股票购买,Carpenter Technology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Carpenter Technology(CRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Carpenter Technology(CRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction